SLC5A2 and urinary bladder cancer: A meta-analysis encompassing 76 trials with over 116,000 participants similarly concluded that SGLT-2 inhibition is unlikely to significantly impact the risk of breast or bladder cancers, adding to the growing consensus that initial safety concerns may have been overstated [343].